Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies

Journal of Interventional Cardiology

Volumn 19, Issue 4, 2006, Pages 319-327

  Alam, Mahboob ^a   Dokainish, Hisham ^a   Lakkis, Nasser ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CREATININE;

ADULT; AGED; ARTERY DISSECTION; ARTICLE; COMPARATIVE STUDY; COMPLETE HEART BLOCK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDLINE; MORTALITY; MUSCLE RESECTION; MYOMECTOMY; OUTCOME ASSESSMENT; PACEMAKER; PERICARDIAL EFFUSION; PRIORITY JOURNAL; SEX RATIO; TIME SERIES ANALYSIS;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; FEMALE; HEART SEPTUM; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 33746876319     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2006.00153.x     Document Type: Article

References (87)

1. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308-1320.
2. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-785.
3. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-2041. Epub 2005 April 11.
4. Jault F, Gandjbakhch I, Rama A, et al. [Long term results of the surgical treatment of obstructive hypertrophic cardiomyopathies]. Arch Mal Coeur Vaiss 1996;89:679-684.
5. Delahaye F, Jegaden O, de Gevigney G, et al. Postoperative and long-term prognosis of myotomy-myomectomy for obstructive hypertrophic cardiomyopathy: Influence of associated mitral valve replacement. Eur Heart J 1993;14:1229-1237.
6. Gueffet JP, Langlard JM, Burban M, et al. [Hypertrophic cardiomyopathy. Long-term clinical development in a regional cohort of 243 patients]. Arch Mal Coeur Vaiss 2001;94:967-974.
7. Krajcer Z, Leachman RD, Cooley DA, et al. Septal myotomymyomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation 1989;80(3 Part 1):I57-I64.
8. Krajcer Z, Leachman RD, Cooley DA, et al. Mitral valve replacement and septal myomectomy in hypertrophic cardiomyopathy. Ten-year follow-up in 80 patients. Circulation 1988;78(3 Part 2):I35-I43.
9. Fighali S, Krajcer Z, Leachman RD. Septal myomectomy and mitral valve replacement for idiopathic hypertrophic subaortic stenosis: Short- and long-term follow-up. J Am Coll Cardiol 1984;3:1127-1134.
10. Fernandes VL, Nagueh SF, Wang W, et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - the Baylor experience (1996-2002). Clin Cardiol 2005;28:124-130.
11. Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 Years of experience. Eur J Echocardiogr 2004;5:347-355.
12. Kuhn H, Seggewiss H, Gietzen FH, et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First inhospital outcome analysis of the German TASH Registry. Z Cardiol 2004;93:23-31.
13. Osterne EC, Seixas TN, Paulo Filho W, et al. Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: Initial experience in the Federal District. Arq Bras Cardiol 2003;80:359-378. Epub 2003 April 29.
14. Tsuchikane E, Takeda Y, Kobayashi T, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Circ J 2003;67:763-767.
15. Rivera S, Sitges M, Azqueta M, et al. [Left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy treated with percutaneous alcohol septal ablation: An echocardiographic study]. Rev Esp Cardiol 2003;56:1174-1181.
16. Dokainish H, Abchee A, Delarosa A, et al. Efficacy and safety of alcohol septal ablation in elderly patients: One year outcome. J Geriatr Cardiol 2005;2:37-39.
17. Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000;83:326-331.
18. Kim JJ, Lee CW, Park SW, et al. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999;83:1220-1223.
19. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342-1354.
20. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
21. Lakkis NM, Nagueh SF, Dunn JK, et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000;36:852-855.
22. Flores-Ramirez R, Lakkis NM, Middleton KJ, et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208-214.
23. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
24. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-1496.
25. Veselka J, Prochazkova S, Bolomova-Homolova I, et al. Effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy on Doppler Tei index: A midterm follow-up. Echocardiography 2005;22:105-109.
26. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999;99:344-347.
27. Seggewiss H, Faber L, Ziemssen P, et al. [One-year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy]. Dtsch Med Wochenschr 2001;126:424-430.
28. van Dockum WG, Beek AM, ten Cate FJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005;111:2503-2508. Epub 2005 May 2.
29. Flores-Ramirez R, Lakkis NM, Middleton KJ, et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208-214.
30. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999;34:1123-1128.
31. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254-261.
32. Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2044-2053.
33. Veselka J, Duchonova R, Prochazkova S, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;60:133-136.
34. Veselka J, Prochazkova S, Duchonova R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interven 2004;63:231-235.
35. Gietzen FH, Leuner CJ, Obergassel L, et al. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: Feasibility, clinical benefit, and short term results in elderly patients. Heart 2004;90:638-644.
36. Gietzen FH, Leuner CJ, Obergassel L, et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 2002;106:454-459.
37. Park TH, Lakkis NM, Middleton KJ, et al. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation 2002;106:412-415.
38. Abraham TP, Nishimura RA, Holmes DR Jr, et al. Strain rate imaging for assessment of regional myocardial function: Results from a clinical model of septal ablation. Circulation 2002;105:1403-1406.
39. Firoozi S, Elliott PM, Sharma S, et al. Septal myotomymyectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-1624.
40. Ruzyllo W, Chojnowska L, Demkow M, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:770-777.
41. Faber L, Seggewiss H, Fassbender D, et al. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results in 66 patients with reference to myocardial contrast echocardiography]. Z Kardiol 1998;87:191-201.
42. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-2421.
43. Veselka J, Duchonova R, Prochazkova S, et al. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005;95:675-678.
44. Chang SM, Lakkis NM, Franklin J, et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109:824-827. Epub 2004 February 16.
45. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: Comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005;129:351-358.
46. Lakkis N, Plana JC, Nagueh S, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol 2001;88:583-586.
47. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-1706.
48. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997;95:2075-2081.
49. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-1755.
50. Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998;32:225-229.
51. Chang SM, Nagueh SF, Spencer WH III, et al. Complete heart block: Determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003;42:296-300.
52. Guo H, Wang J, Chen J, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients. Can J Cardiol 2004;20:779-782.
53. Bhagwandeen R, Woo A, Ross J, et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: Early and intermediate results of a Canadian referral centre. Can J Cardiol 2003;19:912-917.
54. Mutlak D, Gruberg L, Reisner S, et al. Non-surgical myocardial reduction in hypertrophic obstructive cardiomyopathy. Isr Med Assoc J 2002;4:86-90.
55. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000;13:1074-1079.
56. Airoldi F, Di Mario C, Catanoso A, et al. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000;1:200-206.
57. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
58. Li ZQ, Cheng TO, Zhang WW, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: The Chinese experience in 119 patients from a single center. Int J Cardiol 2004;93:197-202. Erratum in: Int J Cardiol 2004 June 3;95(2):363.
59. Monakier D, Woo A, Puri T, et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2004;94:1515-1522.
60. Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr 2000;13:1074-1079.
61. Faber L, Seggewiss H, Welge D, et al. [Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy]. Z Kardiol 2003;92:39-47.
62. Dimitrow PP, Dudek D, Dubeil JS. The risk of alcohol leakage into the left anterior descending coronary artery during non-surgical myocardial reduction in patients with obstructive hypertrophic cardiomyopathy. Eur Heart J 2001;22:437-438.
63. Miric M, Sagic D, Popovic Z, et al. [Percutaneous transluminal ablation of the myocardial septum by embolization of the first branch of the anterior descending coronary artery using a small amount of absolute alcohol]. Srp Arh Celok Lek 2001;129:199-202.
64. Spencer WH III, Roberts R. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy: The need for a registry. Circulation 2000;102:600-601.
65. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): A 5-year experience. Z Kardiol 2000;89:559-564.
66. Kuhn H, Gietzen FH, Leuner C, et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000;89(Suppl. 4):IV41-IV54.
67. Breithardt OA, Stolle B, Franke A, et al. Mid-systolic septal deceleration. A new sign of left ventricular outflow tract obstruction obtained by color-coded tissue Doppler echocardiography. Z Kardiol 2003;92:1003-1007.
68. Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003;91:817-821.
69. Wojtarowicz A, Kornacewicz-Jach Z, Kazmierczak J, et al. [Doppler echocardiographic evaluation of left ventricular diastolic function in patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation in acute and longterm follow up]. Pol Merkuriusz Lek 2002;13:25-28.
70. Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003;91:817-821.
71. Chang S, Sekandarzad MW, Jiang S, et al. Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy. Am Heart J 2003;146:1112-1114.
72. Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal ablation versus surgical septal myectomy: Comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004;44:2329-2332.
73. Kern MJ, Holmes DG, Simpson C, et al. Delayed occurrence of complete heart block without warning after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interven 2002;56:503-507.
74. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, et al. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 1998;80:257-262.
75. Valettas N, Rho R, Beshai J, et al. Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheter Cardiovasc Interven 2003;58:189-193.
76. Cui W, Liu F, Zu X, et al. The relation between His bundle and the first septal perforating artery: Implications for percutaneous transluminal septal myocardial ablation. Int J Cardiol 2004;97:579-580.
77. Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 2004;93:171-175.
78. Nambi V, Buergler JM, Lakkis NM, et al. Effectiveness of percutaneous intervention for patients with obstructive hypertrophic cardiomyopathy and coronary artery disease. Am J Cardiol 2005;96:580-581.
79. Sitges M, Shiota T, Lever HM, et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 2003;91:817-821.
80. Kuhn H, Gietzen FH, Leuner C, et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000;89(Suppl. 4):IV41-IV54.
81. Lawrenz T, Obergassel L, Lieder F, et al Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005;28:295-300.
82. Monakier D, Horlick E, Ross J, et al. Intracoronary myocardial contrast echocardiography in a patient with drug refractory hypertrophic obstructive cardiomyopathy revealing extensive myocardium at risk for infarction with alcohol septal ablation. J Invasive Cardiol 2004;16:482-484.
83. Ten Cate FJ, Bouakaz A, Krenning B, et al. Visualization of myocardial perfusion after percutaneous myocardial septal ablation for hypertrophic cardiomyopathy using superharmonic imaging. J Am Soc Echocardiogr 2003;16:370-372.
84. Okayama H, Sumimoto T, Morioka N, et al. Usefulness of selective myocardial contrast echocardiography in percutaneous transluminal septal myocardial ablation: A case report. Jpn Circ J 2001;65:842-844.
85. Elliott PM, Brecker SJ, McKenna WJ. Left ventricular opacification during selective intracoronary injection of echocardiographic contrast in patients with hypertrophic cardiomyopathy. Heart 2000;83:E7.
86. Kornacewicz-Jach Z, Wojtarowicz A, Goos H, et al. Nuclear magnetic resonance for the assessment of the effects of alcohol septal ablation in hypertrophic cardiomyopathy. Kardiol Pol 2004;61:461-467. English, Polish.
87. van Dockum WG, ten Cate FJ, ten Berg JM, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.